The Company is a pharmaceutical Company developing therapies for the treatment of chronic diseases and conditions with its proprietary drug formulations and delivery platform technologies.


Updates from The Motley Fool

Latest updates on DURECT from Fool.com.
Durect Investors Feel the Pain

Durect ( Nasdaq: DRRX     ) investors just got a painful reminder of what happens when an impo...

Making Cents in Penny Stocks

The occasional shower of pennies from heaven might do our bank accounts some good. Alas, Fools ca...

Why Did My Stock Just Die?

Better-than-expected economic data here at home, coupled with a Europe apparently committed to fi...

3 Stocks Stopping the Presses

You saw the headlines. You know your stock price made a big move. But what does that portend fo...

3 Top Stocks at Half-Price

You love buying your shirts when they go on sale. And who can resist a buy-one-get-one-free offer...

Why Did My Stock Just Die?

Your stock just took a nosedive -- but don't panic. First, let's see whether it had good reason t...

Direct Your Attention to DURECT

Yesterday, tiny drug-delivery expert DURECT ( Nasdaq: DRRX     ) presented at the Merriman C...

Pain-Free Payday for DURECT

Drug-delivery company DURECT ( Nasdaq: DRRX     ) is headed straight to phase 3; it won't get...

Durect's Pain-Free Deal

Sometimes it takes a big partnership deal for investors to get excited over a pharmaceutical comp...



Stock Performance

View Interactive DRRX Charts
Sponsored by

Key Data Points

Primary metrics and data points about DURECT.
Current Price: $1.38
Prev Close: $1.29
Open: $1.27
Bid: $1.27
Ask: $1.39
Day's Range: $1.25 - $1.40
52wk Range: $0.99 - $2.37
Volume: 1,137,475
Avg Vol 490,413
Market Cap: $166M
P/E (ttm): -5.16
EPS (ttm): ($0.25)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about DURECT.
CAPS Rating 2 out of 5
 
88 Outperform
13 Underperform
CAPS All Stars
 
20 Outperform
4 Underperform

How do you think DURECT will perform against the market?



You pick for DURECT is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

James E. Brown, CEO

0% Approve

Based on 1 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for DURECT.

The Company is a pharmaceutical Company developing therapies for the treatment of chronic diseases and conditions with its proprietary drug formulations and delivery platform technologies.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers